For research and educational purposes only. Not medical advice.
GHRP-6 Reference
Educational, not medical advice reference for GHRP-6: GH Release; regulatory status, evidence posture, source review, and schedule notes. Also k…
Reference summary
Early human GH-response work in healthy volunteers documented GH secretion following GHRP-6 administration. Evidence is older and primarily short-term; long-term clinical outcome data are limited, and no modern PK/PD or outcome program comparable to ipamorelin or CJC-1295 exists.
Regulatory and posture
- Categories
- GH Release
- Aliases
- SKF-110679, Growth hormone releasing hexapeptide
- Evidence posture
- translational - Evidence is limited to older, short-term human GH-response studies without modern PK/PD or outcome follow-up. Strong ghrelin-class appetite stimulation is consistently reported.
- Regulatory status
- No FDA-approved GHRP-6 drug label. FDA lists GHRP-6 among bulk drug substances with safety-risk concerns for compounding.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: Bowers 1990 GHRP (GHRP-6) stimulates GH release and is synergistic with GHRH in normal men (J Clin Endocrinol Metab)
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.